Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Current Heart Failure Reports
Erschienen in: Current Heart Failure Reports 2/2017

24.02.2017 | Biomarkers of Heart Failure (W H W Tang and J Grodin, Section Editors)

Endothelial Glycocalyx as Biomarker for Cardiovascular Diseases: Mechanistic and Clinical Implications

verfasst von: Youn-Hyun Kim, Petra Nijst, Kathryn Kiefer, W. H. Wilson Tang

Erschienen in: Current Heart Failure Reports | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Abstract

Introduction

The endothelial surface layer is covered with abundant proteoglycans, of which syndecans and glycosaminoglycans are major constituents.

Recent Findings

Among the endothelial glycocalyx (eGC) constituents, syndecan-1 (sdc1) is a main component, and an elevated serum level of sdc1 may indicate the degradation of eGC. In patients with ischemic heart disease or heart failure, elevation of serum sdc1 has been associated with worsening cardiac and renal function; however, the causal relationship between degradation of eGC and clinical outcomes is unclear.

Summary

Herein, we review the previous literature on eGC in cardiovascular and noncardiovascular diseases and their clinical implications.
Literatur
1.
Constantinescu AA, Vink H, Spaan JA. Endothelial cell glycocalyx modulates immobilization of leukocytes at the endothelial surface. Arterioscler Thromb Vasc Biol. 2003;23(9):1541–7.CrossRefPubMed
2.
Schmidt EP, Yang Y, Janssen WJ, et al. The pulmonary endothelial glycocalyx regulates neutrophil adhesion and lung injury during experimental sepsis. Nat Med. 2012;18(8):1217–23.CrossRefPubMed
3.
Korte S, Wiesinger A, Straeter AS, Peters W, Oberleithner H, Kusche-Vihrog K. Firewall function of the endothelial glycocalyx in the regulation of sodium homeostasis. Pflugers Arch - Eur J Physiol. 2012;463(2):269–78.CrossRef
4.
Siegel G, Malmsten M, Ermilov E. Anionic biopolyelectrolytes of the syndecan/perlecan superfamily: physicochemical properties and medical significance. Adv Colloid Interf Sci. 2014;205:275–318.CrossRef
5.
Maksimenko AV, Turashev AD. No-reflow phenomenon and endothelial glycocalyx of microcirculation. Biochem Res int. 2012;2012:859231.CrossRefPubMed
6.
Weinbaum S, Zhang X, Han Y, Vink H, Cowin SC. Mechanotransduction and flow across the endothelial glycocalyx. Proc Natl Acad Sci U S A. 2003;100(13):7988–95.CrossRefPubMedPubMedCentral
7.
Florian JA, Kosky JR, Ainslie K, Pang Z, Dull RO, Tarbell JM. Heparan sulfate proteoglycan is a mechanosensor on endothelial cells. Circ Res. 2003;93(10):e136–142.CrossRefPubMed
8.
Neves FM, Meneses GC, Sousa NE, et al. Syndecan-1 in acute decompensated heart failure—association with renal function and mortality. Circ J: Off J Jpn Circ Soc. 2015;79(7):1511–9.CrossRef
9.
Tromp J, van der Pol A, Klip IT, et al. Fibrosis marker syndecan-1 and outcome in patients with heart failure with reduced and preserved ejection fraction. Circ Heart Fail. 2014;7(3):457–62.CrossRefPubMed
10.
Meyer S, van der Meer P, van Deursen VM, et al. Neurohormonal and clinical sex differences in heart failure. Eur Heart J. 2013;34(32):2538–47.CrossRefPubMed
11.
Bielecka-Dabrowa A, von Haehling S, Aronow WS, Ahmed MI, Rysz J, Banach M. Heart failure biomarkers in patients with dilated cardiomyopathy. Int J Cardiol. 2013;168(3):2404–10.CrossRefPubMed
12.
Demissei BG, Valente MA, Cleland JG, et al. Optimizing clinical use of biomarkers in high-risk acute heart failure patients. Eur J Heart Fail 2015.
13.
Bielecka-Dabrowa A, Gluba-Brzozka A, Michalska-Kasiczak M, Misztal M, Rysz J, Banach M. The multi-biomarker approach for heart failure in patients with hypertension. Int J Mol Sci. 2015;16(5):10715–33.CrossRefPubMedPubMedCentral
14.
Ostrowski SR, Pedersen SH, Jensen JS, Mogelvang R, Johansson PI. Acute myocardial infarction is associated with endothelial glycocalyx and cell damage and a parallel increase in circulating catecholamines. Crit Care. 2013;17(1):R32.CrossRefPubMedPubMedCentral
15.
Chignalia AZ, Yetimakman F, Christiaans SC, et al.: The glycocalyx and trauma: a review. Shock 2015.
16.
Johansson PI, Stensballe J, Rasmussen LS, Ostrowski SR. A high admission syndecan-1 level, a marker of endothelial glycocalyx degradation, is associated with inflammation, protein C depletion, fibrinolysis, and increased mortality in trauma patients. Ann Surg. 2011;254(2):194–200.CrossRefPubMed
17.
Darwiche SS, Ruan X, Hoffman MK, et al. Selective roles for toll-like receptors 2, 4, and 9 in systemic inflammation and immune dysfunction following peripheral tissue injury. J Trauma Acute Care Surg. 2013;74(6):1454–61.CrossRefPubMedPubMedCentral
18.
Stepp MA, Pal-Ghosh S, Tadvalkar G, Pajoohesh-Ganji A. Syndecan-1 and its expanding list of contacts. Adv Wound Care. 2015;4(4):235–49.CrossRef
19.
Park PW, Pier GB, Hinkes MT, Bernfield M. Exploitation of syndecan-1 shedding by Pseudomonas aeruginosa enhances virulence. Nature. 2001;411(6833):98–102.CrossRefPubMed
20.
Hayashida K, Parks WC, Park PW. Syndecan-1 shedding facilitates the resolution of neutrophilic inflammation by removing sequestered CXC chemokines. Blood. 2009;114(14):3033–43.CrossRefPubMedPubMedCentral
21.
Teng YH, Aquino RS, Park PW. Molecular functions of syndecan-1 in disease. Matrix Biol: J Int Soc Matrix Biol. 2012;31(1):3–16.CrossRef
22.
Stepp MA, Gibson HE, Gala PH, et al. Defects in keratinocyte activation during wound healing in the syndecan-1-deficient mouse. J Cell Sci. 2002;115(Pt 23):4517–31.CrossRefPubMed
23.
Szarvas T, Reis H, Kramer G, et al. Enhanced stromal syndecan-1 expression is an independent risk factor for poor survival in bladder cancer. Hum Pathol. 2014;45(4):674–82.CrossRefPubMed
24.
Nault JC, Guyot E, Laguillier C, et al. Serum proteoglycans as prognostic biomarkers of hepatocellular carcinoma in patients with alcoholic cirrhosis. Cancer Epidemiol Biomarkers Prev. 2013;22(8):1343–52.CrossRefPubMed
25.
Mahtouk K, Hose D, Raynaud P, et al. Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myeloma. Blood. 2007;109(11):4914–23.CrossRefPubMedPubMedCentral
26.
Jilani I, Wei C, Bekele BN, et al. Soluble syndecan-1 (sCD138) as a prognostic factor independent of mutation status in patients with chronic lymphocytic leukemia. Int J Lab Hematol. 2009;31(1):97–105.CrossRefPubMed
27.
Andersen NF, Kristensen IB, Preiss BS, Christensen JH, Abildgaard N. Upregulation of Syndecan-1 in the bone marrow microenvironment in multiple myeloma is associated with angiogenesis. Eur J Haematol. 2015;95(3):211–7.CrossRefPubMed
28.
Larsen AM, Leinoe EB, Johansson PI, Birgens H, Ostrowski SR. High syndecan-1 levels in acute myeloid leukemia are associated with bleeding, thrombocytopathy, endothelial cell damage, and leukocytosis. Leuk Res. 2013;37(7):777–83.CrossRefPubMed
29.
Akl MR, Nagpal P, Ayoub NM, et al. Molecular and clinical profiles of syndecan-1 in solid and hematological cancer for prognosis and precision medicine. Oncotarget. 2015;6(30):28693–715.PubMedPubMedCentral
30.
•• Shinyo Y, Kodama J, Hasengaowa, Kusumoto T, Hiramatsu Y. Loss of cell-surface heparan sulfate expression in both cervical intraepithelial neoplasm and invasive cervical cancer. Gynecol Oncol. 2005;96(3):776–83. Important review providing excellent overview of the Endothelial glycocalyx and its components.
31.
Wang X, Zuo D, Chen Y, et al. Shed Syndecan-1 is involved in chemotherapy resistance via the EGFR pathway in colorectal cancer. Br J Cancer. 2014;111(10):1965–76.CrossRefPubMedPubMedCentral
32.
• Hashimoto Y, Skacel M, Adams JC. Association of loss of epithelial syndecan-1 with stage and local metastasis of colorectal adenocarcinomas: an immunohistochemical study of clinically annotated tumors. BMC Cancer. 2008;8:185. This study investigated functional significance of syndecan-1 in inflammatory process, and the results help to understand the role of endothelial glycocalyx in tissue injury and repair.
33.
Langford JK, Stanley MJ, Cao D, Sanderson RD. Multiple heparan sulfate chains are required for optimal syndecan-1 function. J Biol Chem. 1998;273(45):29965–71.CrossRefPubMed
34.
Nikolova V, Koo CY, Ibrahim SA, et al. Differential roles for membrane-bound and soluble syndecan-1 (CD138) in breast cancer progression. Carcinogenesis. 2009;30(3):397–407.CrossRefPubMed
35.
Purushothaman A, Uyama T, Kobayashi F, et al. Heparanase-enhanced shedding of syndecan-1 by myeloma cells promotes endothelial invasion and angiogenesis. Blood. 2010;115(12):2449–57.CrossRefPubMedPubMedCentral
36.
Maeda T, Desouky J, Friedl A. Syndecan-1 expression by stromal fibroblasts promotes breast carcinoma growth in vivo and stimulates tumor angiogenesis. Oncogene. 2006;25(9):1408–12.CrossRefPubMed
37.
Becker BF, Jacob M, Leipert S, Salmon AH, Chappell D. Degradation of the endothelial glycocalyx in clinical settings: searching for the sheddases. Br J Clin Pharmacol. 2015;80(3):389–402.CrossRefPubMedPubMedCentral
38.
Fukai N, Kenagy RD, Chen L, Gao L, Daum G, Clowes AW. Syndecan-1: an inhibitor of arterial smooth muscle cell growth and intimal hyperplasia. Arterioscler Thromb Vasc Biol. 2009;29(9):1356–62.CrossRefPubMedPubMedCentral
39.
Angsana J, Chen J, Smith S, et al. Syndecan-1 modulates the motility and resolution responses of macrophages. Arterioscler Thromb Vasc Biol. 2015;35(2):332–40.CrossRefPubMed
40.
Vanhoutte D, Schellings MW, Gotte M, et al. Increased expression of syndecan-1 protects against cardiac dilatation and dysfunction after myocardial infarction. Circulation. 2007;115(4):475–82.CrossRefPubMed
41.
Schellings MW, Vanhoutte D, van Almen GC, et al. Syndecan-1 amplifies angiotensin II-induced cardiac fibrosis. Hypertension. 2010;55(2):249–56.CrossRefPubMed
42.
Jacob M, Saller T, Chappell D, Rehm M, Welsch U, Becker BF. Physiological levels of A-, B- and C-type natriuretic peptide shed the endothelial glycocalyx and enhance vascular permeability. Basic Res Cardiol. 2013;108(3):347.CrossRefPubMed
43.
Jacob M, Rehm M, Loetsch M, et al. The endothelial glycocalyx prefers albumin for evoking shear stress-induced, nitric oxide-mediated coronary dilatation. J Vasc Res. 2007;44(6):435–43.CrossRefPubMed
44.
Becker BF, Chappell D, Jacob M. Endothelial glycocalyx and coronary vascular permeability: the fringe benefit. Basic Res Cardiol. 2010;105(6):687–701.CrossRefPubMed
45.
• Hollmann J, Schmidt A, von Bassewitz DB, Buddecke E. Relationship of sulfated glycosaminoglycans and cholesterol content in normal and arteriosclerotic human aorta. Arteriosclerosis. 1989;9(2):154–8. Clinical investigation into the utility of syndecan-1 as a biomarker in acute decompensated heart failure.
46.
• Papakonstantinou E, Roth M, Block LH, Mirtsou-Fidani V, Argiriadis P, Karakiulakis G. The differential distribution of hyaluronic acid in the layers of human atheromatic aortas is associated with vascular smooth muscle cell proliferation and migration. Atherosclerosis. 1998;138(1):79–89. Clinical investigation into the utility of syndecan-1 as a biomarker in acute decompensated heart failure.
47.
• Soto Y, Mesa N, Alfonso Y, et al. Targeting arterial wall sulfated glycosaminoglycans in rabbit atherosclerosis with a mouse/human chimeric antibody. mAbs. 2014;6(5):1340–6. Clinical investigation into the utility of syndecan-1 as a biomarker in acute decompensated heart failure.
48.
Miranda CH, de Carvalho BM, Schmidt A, Marin-Neto JA, Pazin-Filho A. Evaluation of the endothelial glycocalyx damage in patients with acute coronary syndrome. Atherosclerosis. 2016;247:184–8.CrossRefPubMed
49.
• Vink H, Duling BR. Identification of distinct luminal domains for macromolecules, erythrocytes, and leukocytes within mammalian capillaries. Circ Res. 1996;79(3):581–9. Endothelial glycocalyx was demonstrated as true interface between blood and capillary walls.
50.
Vink H, Duling BR. Capillary endothelial surface layer selectively reduces plasma solute distribution volume. Am J Phys Heart Circ Phys. 2000;278(1):H285–289.
51.
52.
Ebong EE, Macaluso FP, Spray DC, Tarbell JM. Imaging the endothelial glycocalyx in vitro by rapid freezing/freeze substitution transmission electron microscopy. Arterioscler Thromb Vasc Biol. 2011;31(8):1908–15.CrossRefPubMedPubMedCentral
53.
Gretz JE, Duling BR. Measurement uncertainties associated with the use of bright-field and fluorescence microscopy in the microcirculation. Microvasc Res. 1995;49(1):134–40.CrossRefPubMed
54.
Kataoka H, Ushiyama A, Kawakami H, Akimoto Y, Matsubara S, Iijima T. Fluorescent imaging of endothelial glycocalyx layer with wheat germ agglutinin using intravital microscopy. Microsc Res Tech. 2016;79(1):31–7.CrossRefPubMed
55.
Nieuwdorp M, Meuwese MC, Mooij HL, et al. Measuring endothelial glycocalyx dimensions in humans: a potential novel tool to monitor vascular vulnerability. J Appl Physiol. 2008;104(3):845–52.CrossRefPubMed
56.
Vlahu CA, Lemkes BA, Struijk DG, Koopman MG, Krediet RT, Vink H. Damage of the endothelial glycocalyx in dialysis patients. J Am Soc Nephrol: JASN. 2012;23(11):1900–8.CrossRefPubMedPubMedCentral
57.
Rehm M, Haller M, Orth V, et al. Changes in blood volume and hematocrit during acute preoperative volume loading with 5% albumin or 6% hetastarch solutions in patients before radical hysterectomy. Anesthesiology. 2001;95(4):849–56.CrossRefPubMed
58.
Nieuwdorp M, van Haeften TW, Gouverneur MC, et al. Loss of endothelial glycocalyx during acute hyperglycemia coincides with endothelial dysfunction and coagulation activation in vivo. Diabetes. 2006;55(2):480–6.CrossRefPubMed
59.
60.
Cook NR. Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation. 2007;115(7):928–35.CrossRefPubMed
61.
Harrell Jr FE, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15(4):361–87.CrossRefPubMed
62.
Leening MJ, Vedder MM, Witteman JC, Pencina MJ, Steyerberg EW. Net reclassification improvement: computation, interpretation, and controversies: a literature review and clinician’s guide. Ann Intern Med. 2014;160(2):122–31.CrossRefPubMed
63.
Pencina MJ, D’Agostino Sr RB, Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med. 2011;30(1):11–21.CrossRefPubMed
64.
Pencina MJ, D’Agostino Sr RB, D’Agostino Jr RB, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2008;27(2):157–72. discussion 207–112.CrossRefPubMed
65.
Bethell DB, Gamble J, Pham PL, et al. Noninvasive measurement of microvascular leakage in patients with dengue hemorrhagic fever. Clin infect Dis: Off Publ Infect Dis Soc Am. 2001;32(2):243–53.CrossRef
66.
Takishima I, Nakamura T, Hirano M, et al. Predictive value of serial assessment of endothelial function in chronic heart failure. Int J Cardiol. 2012;158(3):417–22.CrossRefPubMed
67.
Salmito FT, de Oliveira Neves FM, Meneses GC, de Almeida Leitao R, Martins AM, Liborio AB. Glycocalyx injury in adults with nephrotic syndrome: association with endothelial function. Clin Chim Acta; Int J Clin Chem. 2015;447:55–8.CrossRef
68.
Pahwa R, Nallasamy P, Jialal I: Toll-like receptors 2 and 4 mediate hyperglycemia induced macrovascular aortic endothelial cell inflammation and perturbation of the endothelial glycocalyx. J Diabetes Complicat. 2016.
69.
Lee JF, Barrett-O’Keefe Z, Garten RS, et al. Evidence of microvascular dysfunction in heart failure with preserved ejection fraction. Heart. 2015.
70.
Marechaux S, Samson R, van Belle E, et al. Vascular and microvascular endothelial function in heart failure with preserved ejection fraction. J Card Fail. 2016;22(1):3–11.CrossRefPubMed
71.
Titze J, Machnik A. Sodium sensing in the interstitium and relationship to hypertension. Curr Opin Nephrol Hypertens. 2010;19(4):385–92.CrossRefPubMed
72.
Heer M, Baisch F, Kropp J, Gerzer R, Drummer C. High dietary sodium chloride consumption may not induce body fluid retention in humans. Am J Physiol Renal physiol. 2000;278(4):F585–595.PubMed
73.
Machnik A, Neuhofer W, Jantsch J, et al. Macrophages regulate salt-dependent volume and blood pressure by a vascular endothelial growth factor-C-dependent buffering mechanism. Nat Med. 2009;15(5):545–52.CrossRefPubMed
74.
• Titze J, Shakibaei M, Schafflhuber M, et al. Glycosaminoglycan polymerization may enable osmotically inactive Na + storage in the skin. Am J Phys Heart Circ Phys. 2004;287(1):H203–208. This study suggested endothelial glycocalyx can store osmotically inactive sodium by demonstrating glycocalyx in skin work as a sodium reservoir.
75.
Olde Engberink RH, Rorije NM. Homan van der Heide JJ, van den Born BJ, Vogt L: Role of the vascular wall in sodium homeostasis and salt sensitivity. J Am Soc Nephrol: JASN. 2015;26(4):777–83.CrossRefPubMed
76.
Siegel G, Walter A, Kauschmann A, Malmsten M, Buddecke E. Anionic biopolymers as blood flow sensors. Biosens bioelectron. 1996;11(3):281–94.CrossRefPubMed
77.
Siegel G, Malmsten M, Klussendorf D, Walter A, Schnalke F, Kauschmann A. Blood-flow sensing by anionic biopolymers. J Auton Nerv Syst. 1996;57(3):207–13.CrossRefPubMed
78.
Pries AR, Secomb TW, Gaehtgens P. The endothelial surface layer. Pflugers Arch - Eur J Physiol. 2000;440(5):653–66.CrossRef
79.
Jeansson M, Haraldsson B. Morphological and functional evidence for an important role of the endothelial cell glycocalyx in the glomerular barrier. Am J Physiol Renal Physiol. 2006;290(1):F111–116.CrossRefPubMed
80.
Xu C, Wu X, Hack BK, Bao L, Cunningham PN. TNF causes changes in glomerular endothelial permeability and morphology through a Rho and myosin light chain kinase-dependent mechanism. Phys Rep. 2015;3(12).
81.
Adamson RH. Permeability of frog mesenteric capillaries after partial pronase digestion of the endothelial glycocalyx. J Physiol. 1990;428:1–13.CrossRefPubMedPubMedCentral
82.
Nieuwdorp M, Mooij HL, Kroon J, et al. Endothelial glycocalyx damage coincides with microalbuminuria in type 1 diabetes. Diabetes. 2006;55(4):1127–32.CrossRefPubMed
83.
Chappell D, Bruegger D, Potzel J, et al. Hypervolemia increases release of atrial natriuretic peptide and shedding of the endothelial glycocalyx. Crit Care. 2014;18(5):538.CrossRefPubMedPubMedCentral
84.
Oberleithner H, Peters W, Kusche-Vihrog K, et al. Salt overload damages the glycocalyx sodium barrier of vascular endothelium. Pflugers Arch - Eur J Physiol. 2011;462(4):519–28.CrossRef
85.
Rehm M, Bruegger D, Christ F, et al. Shedding of the endothelial glycocalyx in patients undergoing major vascular surgery with global and regional ischemia. Circulation. 2007;116(17):1896–906.CrossRefPubMed
86.
Grundmann S, Fink K, Rabadzhieva L, et al. Perturbation of the endothelial glycocalyx in post cardiac arrest syndrome. Resuscitation. 2012;83(6):715–20.CrossRefPubMed
87.
Annecke T, Fischer J, Hartmann H, et al. Shedding of the coronary endothelial glycocalyx: effects of hypoxia/reoxygenation vs ischaemia/reperfusion. Br J Anaesth. 2011;107(5):679–86.CrossRefPubMed
88.
Becker BF, Fischer J, Hartmann H, et al. Inosine, not adenosine, initiates endothelial glycocalyx degradation in cardiac ischemia and hypoxia. Nucleosides Nucleotides Nucleic Acids. 2011;30(12):1161–7.CrossRefPubMed
89.
Gilles S, Zahler S, Welsch U, Sommerhoff CP, Becker BF. Release of TNF-alpha during myocardial reperfusion depends on oxidative stress and is prevented by mast cell stabilizers. Cardiovasc Res. 2003;60(3):608–16.CrossRefPubMed
90.
Donati A, Domizi R, Damiani E, Adrario E, Pelaia P, Ince C. From macrohemodynamic to the microcirculation. Crit Care Res Prac. 2013;2013:892710.
91.
Sakr Y, Dubois MJ, De Backer D, Creteur J, Vincent JL. Persistent microcirculatory alterations are associated with organ failure and death in patients with septic shock. Crit Care Med. 2004;32(9):1825–31.CrossRefPubMed
92.
93.
Chappell D, Jacob M, Hofmann-Kiefer K, et al. Hydrocortisone preserves the vascular barrier by protecting the endothelial glycocalyx. Anesthesiology. 2007;107(5):776–84.CrossRefPubMed
94.
Zeng Y, Liu XH, Tarbell J, Fu B. Sphingosine 1-phosphate induced synthesis of glycocalyx on endothelial cells. Exp Cell Res. 2015;339(1):90–5.CrossRefPubMed
95.
Zeng Y, Adamson RH, Curry FR, Tarbell JM. Sphingosine-1-phosphate protects endothelial glycocalyx by inhibiting syndecan-1 shedding. Am J Phys Heart Circ Phys. 2014;306(3):H363–372.
96.
Torres LN, Sondeen JL, Ji L, Dubick MA, Torres Filho I. Evaluation of resuscitation fluids on endothelial glycocalyx, venular blood flow, and coagulation function after hemorrhagic shock in rats. J Trauma Acute Care surg. 2013;75(5):759–66.CrossRefPubMed
97.
Torres Filho I, Torres LN, Sondeen JL, Polykratis IA, Dubick MA. In vivo evaluation of venular glycocalyx during hemorrhagic shock in rats using intravital microscopy. Microvasc Res. 2013;85:128–33.CrossRefPubMed
98.
Straat M, Muller MC, Meijers JC, et al. Effect of transfusion of fresh frozen plasma on parameters of endothelial condition and inflammatory status in non-bleeding critically ill patients: a prospective substudy of a randomized trial. Crit Care. 2015;19:163.CrossRefPubMedPubMedCentral
99.
Chappell D, Hofmann-Kiefer K, Jacob M, et al. TNF-alpha induced shedding of the endothelial glycocalyx is prevented by hydrocortisone and antithrombin. Basic Res Cardiol. 2009;104(1):78–89.CrossRefPubMed
100.
Chappell D, Dorfler N, Jacob M, et al. Glycocalyx protection reduces leukocyte adhesion after ischemia/reperfusion. Shock. 2010;34(2):133–9.CrossRefPubMed
101.
Potter DR, Jiang J, Damiano ER. The recovery time course of the endothelial cell glycocalyx in vivo and its implications in vitro. Circ Res. 2009;104(11):1318–25.CrossRefPubMedPubMedCentral
102.
Giantsos-Adams KM, Koo AJ, Song S, et al. Heparan sulfate regrowth profiles under laminar shear flow following enzymatic degradation. Cell Mol Bioeng. 2013;6(2):160–74.CrossRefPubMedPubMedCentral
103.
Koo A, Dewey Jr CF, Garcia-Cardena G. Hemodynamic shear stress characteristic of atherosclerosis-resistant regions promotes glycocalyx formation in cultured endothelial cells. Am J Physiol Cell Physiol. 2013;304(2):C137–146.CrossRefPubMed
104.
Voyvodic PL, Min D, Liu R, et al. Loss of syndecan-1 induces a pro-inflammatory phenotype in endothelial cells with a dysregulated response to atheroprotective flow. J Biol Chem. 2014;289(14):9547–59.CrossRefPubMedPubMedCentral
Metadaten
Titel
Endothelial Glycocalyx as Biomarker for Cardiovascular Diseases: Mechanistic and Clinical Implications
verfasst von
Youn-Hyun Kim
Petra Nijst
Kathryn Kiefer
W. H. Wilson Tang
Publikationsdatum
24.02.2017
Verlag
Springer US
Erschienen in
Current Heart Failure Reports / Ausgabe 2/2017
Print ISSN: 1546-9530
Elektronische ISSN: 1546-9549
DOI
https://doi.org/10.1007/s11897-017-0320-5

Weitere Artikel der Ausgabe 2/2017

Current Heart Failure Reports 2/2017 Zur Ausgabe

Clinical Trials (J Butler, Section Editor)

Registry-Based Pragmatic Trials in Heart Failure: Current Experience and Future Directions

Pathophysiology: Neuroendocrine, Vascular, and Metabolic Factors (S Katz, Section Editor)

Orexin: a Missing Link Between Sleep Disorders and Heart Failure?

Self-Care and Health Outcomes (R Gallagher and R Clark, Section Editors)

Role of the Pharmacist for Improving Self-care and Outcomes in Heart Failure

Self-Care and Health Outcomes (R Gallagher and R Clark, Section Editors)

Factors Related to Self-Care in Heart Failure Patients According to the Middle-Range Theory of Self-Care of Chronic Illness: a Literature Update

Pharmacologic Therapy (W H W Tang, Section Editor)

Diuretic Strategies in Acute Decompensated Heart Failure

Biomarkers of Heart Failure (W H W Tang and J Grodin, Section Editors)

Clinical Phenotyping of Heart Failure with Biomarkers: Current and Future Perspectives

Neu im Fachgebiet Kardiologie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

21.05.2024 TAVI Nachrichten

Bei schwerer Aortenstenose und obstruktiver KHK empfehlen die Leitlinien derzeit eine chirurgische Kombi-Behandlung aus Klappenersatz plus Bypass-OP. Diese Empfehlung wird allerdings jetzt durch eine aktuelle Studie infrage gestellt – mit überraschender Deutlichkeit.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen